IGC Pharma, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IGC research report →
Price Chart
About the company
IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates aimed at this disease: IGC-AD1, which is presently undergoing a Phase 2 clinical study for addressing agitation associated with Alzheimer's-related dementia, and TGR-63, which is still in its preclinical stage.
- CEO
- Ram Mukunda
- IPO
- 2006
- Employees
- 70
- HQ
- Potomac, MD, US
Get TickerSpark's AI analysis on IGC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $19.60M
- P/E
- -2.24
- PEG
- 0.18
- P/S
- 17.04
- P/B
- 3.10
- EV/EBITDA
- -2.82
- Div Yield
- 0.00%
- Gross Margin
- 16.51%
- Op Margin
- -802.70%
- Net Margin
- -643.65%
- ROE
- -123.93%
- ROIC
- -137.23%
Latest fiscal year · YoY change
- Revenue
- $1.19M-6.7%
- Gross Profit
- $352.00K-43.1%
- Op Income
- $-10,203,000
- Net Income
- $-6,548,000+8.0%
- EPS
- $-0.07+22.3%
- OCF Growth
- -23.9%
- FCF Growth
- -15.7%
- 52W High
- $0.36
- 52W Low
- $0.08
- 50D MA
- $0.24
- 200D MA
- $0.27
- Beta
- 0.49
- RSI (14)
- 32
- Avg Volume
- 615.25K
No earnings-call transcripts are available for IGC yet.
- Free Float
- 74.1%
- Shares Outstanding
- 116.69M
- Float Shares
- 86.49M
of shares held by institutions
37 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 1.15M | 0 |
| Geode Capital Management, LLC | 1.04M | ▲ 161.74K |
| Advisorshares Investments LLC | 939.48K | ▲ 261.00K |
| Vanguard Capital Management LLC | 870.71K | ▲ 55.80K |
| Citadel Advisors LLC | 735.69K | ▲ 298.38K |
| Blackrock, Inc. | 703.80K | 0 |
| Renaissance Technologies LLC | 653.46K | ▲ 366.85K |
| Vanguard Fiduciary Trust Co | 419.41K | 0 |
| State Street Corp | 274.90K | ▲ 74.10K |
| Northern Trust Corp | 170.27K | 0 |
| Ubs Group AG | 98.72K | ▲ 98.72K |
| Goldman Sachs Group Inc | 65.54K | 0 |
Held by 7 ETFs
Biggest fund positions in IGC by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 25, 26 | Mukunda Ram | other | 100,000 |
| Sep 25, 26 | Mukunda Ram | other | 100,000 |
| Sep 25, 26 | GRIMALDI CLAUDIA | other | 150,000 |
| Jun 30, 26 | Mukunda Ram | other | 2,226,475 |
| Jun 30, 26 | GRIMALDI CLAUDIA | other | 2,048,378 |
| Apr 1, 26 | PRINS RICHARD K | other | 70,000 |
| Apr 1, 26 | PRINS RICHARD K | other | 100,000 |
| Apr 1, 26 | PRINS RICHARD K | other | 70,000 |
| Apr 1, 26 | PRINS RICHARD K | other | 100,000 |
| Apr 1, 26 | Mukunda Ram | other | 323,077 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our IGC coverage
Recent articles, reports, and earnings notes.
No research on IGC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IGC report →IGC Pharma Unveils PRISM AI Platform to Move Alzheimer's Risk Prediction to Brain-Health Action and Commercial Deployment
accessnewswire.com · Oct 13
IGC Pharma, Inc. (NYSEAMERICAN:IGC) Stock Short Interest Jumps 48.0%
defenseworld.net · Oct 3
IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer's Trial; Topline Results Expected Q4 2026
accessnewswire.com · Sep 28
IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure
accessnewswire.com · Aug 17
IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline Readout
accessnewswire.com · Aug 11
IGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short Campaign
accessnewswire.com · Jul 29
IGC Pharma to Showcase AI Portfolio at AAIC 2026, Including AHA Platform That Reduced Alzheimer's Data Harmonization Time by 90% in Representative Workflow
accessnewswire.com · Jul 9
IGC Pharma CEO and Principal Financial Officer Purchase More Than $1.15 Million of Common Stock Directly from the Company
accessnewswire.com · Jul 7
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.